Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.92USD
3:59pm EST
Change (% chg)

$-0.37 (-6.99%)
Prev Close
$5.29
Open
$5.36
Day's High
$5.36
Day's Low
$4.90
Volume
254,111
Avg. Vol
198,050
52-wk High
$6.30
52-wk Low
$3.64

Chart for

About

Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery... (more)

Overall

Beta: 1.81
Market Cap(Mil.): $484.02
Shares Outstanding(Mil.): 91.50
Dividend: --
Yield (%): --

Financials

  INO.OQ Industry Sector
P/E (TTM): -- 81.01 29.57
EPS (TTM): -0.94 -- --
ROI: -60.47 -0.53 12.77
ROE: -64.38 -3.22 14.47

BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV Patients

* INOVIO OPENS PHASE 2 TRIAL FOR VGX-3100 IN THIRD INDICATION TO TREAT HPV – THE NO. 1 SEXUALLY TRANSMITTED DISEASE

May 21 2018

BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial

* INOVIO HIV VACCINE, WHICH GENERATED NEAR 100% IMMUNE RESPONSES, SUSTAINED DURABLE MEMORY RESPONSES MEASURED ONE YEAR AFTER THE START OF CLINICAL TRIAL Source text for Eikon: Further company coverage:

May 15 2018

Earnings vs. Estimates